MeiraGTx Holdings PLC
meiragtx.comWhat Do They Do?
Develops genetic medicines for people with inherited and other diseases, and manufactures gene therapy products for pharmaceutical partners.
10-K for FY2025, filed Mar 30, 2026
How Do They Make Money?
License agreements bring most revenue: partners pay upfront and when development or sales milestones are reached, and some agreements can also yield royalties. MeiraGTx also earns service revenue from research, development and manufacturing work for collaborators.
10-K for FY2025, filed Mar 30, 2026On January 30, 2019, we and our wholly-owned subsidiary MeiraGTx UK II Limited entered into a Collaboration, Option and License Agreement…View ↗
Under the Asset Purchase Agreement, Johnson & Johnson Innovative Medicine paid us a non-refundable upfront cash purchase price of $65.0…View ↗
At contract inception, the Company assesses the goods or services promised within the contract to determine whether each promised good or…View ↗
-
10-K for FY2025, filed Mar 30, 2026
FY2025 revenue by product or service ↗
$81.4M
-
10-K for FY2025, filed Mar 30, 2026
$81.4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Service revenue - related party
|
7.9% |
Service revenue - related party, FY2025
$6.4M Sources
|
|
|
License revenue
Licensed
10-K for FY2025, filed Mar 30, 2026 |
92% |
License revenue, FY2025
$75M Sources
|
Licensed |
Who Are Their Customers?
Biopharmaceutical collaborators deal directly with MeiraGTx for licenses and research, development and manufacturing services.
10-K for FY2025, filed Mar 30, 2026
Do Revenues Turn Into Profits?
No. It lost $114.2M in FY2025.
10-K for FY2025, filed Mar 30, 2026
−$106MView ↗
10-K for FY2025, filed Mar 30, 2026
−$114.2MView ↗
10-K for FY2025, filed Mar 30, 2026
−$50.2MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
$160.7MView ↗
- ▲ Now profitable
- vs −$38.8M in Q2 FY2025
-
Aug 13, 2026
Acquired full rights to bota-vec from Johnson & Johnson
The deal includes contingent regulatory and sales payments plus royalties on global sales.
Sources
8-K, filed Aug 13, 2026
Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis…View ↗
-
Apr 24, 2026
Completed initial closing of Hologen neuroscience collaboration
The agreement covers genetic medicines for Parkinson’s and genetic obesity disorders, plus a gene-delivery device.
Sources
8-K, filed Apr 24, 2026
On April 20, 2026 (the “Initial Closing Date”), MeiraGTx Holdings plc (the “Company”) and certain of its affiliates completed the initial…View ↗
Growing. Revenue grew 2.2x in 4 years, from $37.7M in FY2021 to $81.4M in FY2025, about 21% a year.
Who Do They Compete With?
Competes with Spark Therapeutics, Voyager Therapeutics, and Lilly
10-K for FY2025, filed Mar 30, 2026There are other organizations working to improve existing therapies or to develop new therapies for our initially selected disease…View ↗
Loading...
